SCHEMBL4917815

SCHEMBL4917815

NN=Cc1cc2ccccc2o1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.58
CA2 P00918 3/20 0.46
FLT3 P36888 1/20 0.44
LOXL2 Q9Y4K0 1/20 0.44
APP P05067 1/20 0.44
POLB P06746 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CA1 P00915 2/20 0.42
CA9 Q16790 2/20 0.42
CA12 O43570 1/20 0.42
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
MAPK1 P28482 2/20 0.42
MAPT P10636 1/20 0.42
TDP1 Q9NUW8 2/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
AGXT P21549 1/20 0.41
PIM1 P11309 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MGLL Q99685 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16693057 0.81 CYP2A6 (0.58) CYP2A6FLT3LOXL2APPPOLB
SCHEMBL533466 0.81 CYP2A6 (0.58) CYP2A6FLT3LOXL2APPPOLB
SCHEMBL3979881 0.74 CYP2A6 (0.50) CYP2A6APPSMN1; SMN2RAB9ANPC1
SCHEMBL3979876 0.74 CYP2A6 (0.50) CYP2A6APPSMN1; SMN2RAB9ANPC1
SCHEMBL17185672 0.74 CYP2A6 (0.64) CYP2A6CA2FLT3LOXL2APP
SCHEMBL11396362 0.74 CYP2A6 (0.64) CYP2A6CA2FLT3LOXL2APP
SCHEMBL2900756 0.74 CYP2A6 (0.64) CYP2A6CA2FLT3LOXL2APP
SCHEMBL9956377 0.74 CYP2A6 (1.00) CYP2A6CA2FLT3LOXL2APP
SCHEMBL91009 0.74 CYP2A6 (1.00) CYP2A6CA2FLT3LOXL2APP
SCHEMBL1706926 0.74 CYP2A6 (0.64) CYP2A6CA2FLT3LOXL2APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0299973-B1 ANTHELMINTIC ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS THE UPJOHN COMPANY (US) 1992-06-17 EP claimed
EP-0299973-A1 ANTHELMINTIC ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS. UPJOHN CO (US) 1989-01-25 EP claimed
WO-1987006133-A1 ANTHELMINTIC ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS THE UPJOHN COMPANY (US) 1987-10-22 WO claimed
US-20080064730-A1 Azine Compounds for Combating Animal Pests BASF AKTIENGESELLSCHAFT (DE) 2008-03-13 US disclosed
EP-1827102-A1 AZINE COMPOUNDS FOR COMBATING ANIMAL PESTS BASF AKTIENGESELLSCHAFT (DE) 2007-09-05 EP disclosed
WO-2006056462-A9 AZINE COMPOUNDS FOR COMBATING ANIMAL PESTS BASF AG (DE) 2007-07-26 WO disclosed
WO-2006056462-A1 AZINE COMPOUNDS FOR COMBATING ANIMAL PESTS BASF AKTIENGESELLSCHAFT (DE) 2006-06-01 WO disclosed
EP-1631143-A1 HYDRAZONE DERIVATIVES FOR COMBATTING HARMFUL INSECTS AND ARACHNIDS BASF AKTIENGESELLSCHAFT (DE) 2006-03-08 EP disclosed
WO-2004105488-A1 HYDRAZONE DERIVATIVES FOR COMBATTING HARMFUL INSECTS AND ARACHNIDS BASF AKTIENGESELLSCHAFT (DE) 2004-12-09 WO disclosed
EP-0299973-B1 ANTHELMINTIC ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS THE UPJOHN COMPANY (US) 1992-06-17 EP disclosed
EP-0299973-A1 ANTHELMINTIC ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS. UPJOHN CO (US) 1989-01-25 EP disclosed
WO-1987006133-A1 ANTHELMINTIC ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS THE UPJOHN COMPANY (US) 1987-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064730-A1 Azine Compounds for Combating Animal Pests PARK7, OR10J3, TAS2R7 CYP2A6 1409/4885CA2 2648/4885FLT3 4233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.